BMO Capital Reiterates Outperform on Pepsi (PEP) Following Solid 3Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/16/2024
- Wall Street stocks close lower on higher Treasury yields, rate expectations
- Powell says recent inflation data point to need to keep rates higher for longer
- United Airlines maintains forecast after Q1 results top Wall Street estimates
- UnitedHealth (UNH) beats earnings, revenue estimates in Q1; shares up
- Bank of America profit hurt by losses on credit cards, office loans
- Trump Media & Technology Group (DJT) Files S-1
- Tesla (TSLA) Senior VP Drew Baglino Is Said To Leave The Company - Bloomberg
- GE HealthCare (GEHC) Announces Resignation of Jan Makela, CEO of Imaging
- General Motors (GM) Said to be Moving Detroit HQ to Dan Gilbert's Hudson Tower - Bloomberg
- Biohaven Pharma (BHVN) presents update on degrader platform and summary of progress to date in Phase 1 single ascending dose study for BHV-1300
- After-hours movers: United Airlines, J.B. Hunt, and more
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
Senomyx (SNMX) Extends PepsiCo Deal for 3 Years
September 30, 2016 8:33 AM EDTSenomyx, Inc. (NASDAQ: SNMX), a leading company using proprietary taste science technologies to discover, develop, and commercialize novel flavor ingredients for the food, beverage, and ingredient supply industries, announced today that it has amended and restated its Sweet Taste Program... More
Jefferies Cuts Price Target on Pepsi (PEP) to $122; Reiterates Buy
September 30, 2016 7:56 AM EDTJefferies maintained a Buy rating on Pepsico (NYSE: PEP), and cut the price target to $122.00 (from $124.00), following the company's 3Q earnings report. PEPs $1.40 in EPS came in 6% ahead of the Street's estimate on a strong topline 4.2% org sales vs. 2.7% estimates.
Analyst Kevin... More
Dunkin' partners with Coca-Cola on bottled coffee
September 29, 2016 12:49 PM EDT(Reuters) - Dunkin' Brands Group Inc (NASDAQ: DNKN) said on Thursday its doughnut chain will partner with Coca-Cola Co (NYSE: KO) to launch a line of bottled coffee beverages in the United States, its first foray into the ready-to-drink coffee market dominated by rival Starbucks Corp (NASDAQ: SBUX).
The Dunkin' Donuts chain operator said the beverages, set to launch in early 2017,... More
Pepsi (PEP) volatility decreases as shares rally on Q3 and raised guidance
September 29, 2016 12:20 PM EDTPepsi (NYSE: PEP) is recently up $1.17 to $108.55 after reporting better than expected Q3 revenue and earnings and raising its FY16 core constant currency EPS growth guidance to up 10% from up 9%. September weekly call option implied volatility is at 16, October is at 13; compared to its 52-week range of 11 to 22.
... MoreStreetinsider.com's Hot Lunchtime Reads 9/29: (VRX) (AGN) (PEP) (ARRS) (IBM)
September 29, 2016 12:16 PM EDTThe following is a list of notable articles to help get you through the lunch hour:Valeant Pharma (VRX), Other Pharma Stocks Weaker as Clinton Op-Ed Discusses Measures on Drug Prices ->... More
Pepsi (PEP) volatility comes in as shares rally on Q3 and raised guidance
September 29, 2016 12:13 PM EDTPepsi (NYSE: PEP) is recently up $1.17 to $108.55 after reporting better than expected Q3 revenue and earnings and raising its FY16 core constant currency EPS growth guidance to up 10% from up 9%. September weekly call option implied volatility is at 16, October is at 13; compared to its 52-week range of 11 to 22.
... MorePre-Open Stock Movers 09/29: (AEGR) (ARWR) (EBAY) Higher; (ITCI) (ADHD) (FIT) Lower (more...)
September 29, 2016 8:52 AM EDTToday's After-Hours Movers
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) 63.2% LOWER; announced top-line results from the second Phase 3 clinical trial (Study 302) of ITI-007, an oral, first-in-class investigational medicine for the treatment of schizophrenia. In this trial, neither dose of ITI-007 separated from placebo on the primary endpoint, change from baseline on the Positive and Negative Syndrome Scale (PANSS) total score, in the pre-defined patient population. The active control, risperidone, did separate from placebo. In this trial, ITI-007 was statistically significantly better than risperidone on key safety and tolerability parameters... More
Pepsi (PEP) Tops Q3 EPS by 8c
September 29, 2016 6:31 AM EDTPepsi (NYSE: PEP) reported Q3 EPS of $1.40, $0.08 better than the analyst estimate of $1.32. Revenue for the quarter came in at $16 billion versus the consensus estimate of $15.83 billion.
GUIDANCE:
Pepsi sees FY2016 EPS of $4.78, versus the consensus of... More
Trading Radar for 9/29: Pepsi (PEP), Accenture (ACN), Costco (COST), ConAgra (CAG) Report
September 28, 2016 2:40 PM EDTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Economics:
8:30am EDT
PepsiCo (PEP) September weekly implied volatility increases into Q3 and outlook
September 28, 2016 12:24 PM EDTPepsi (NYSE: PEP) September weekly call option implied volatility is at 28, October is at 14; compared to its 52-week range of 11 to 22 into the expected release of Q3 results on September 29.
... More
